<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371579</url>
  </required_header>
  <id_info>
    <org_study_id>06-125</org_study_id>
    <nct_id>NCT00371579</nct_id>
  </id_info>
  <brief_title>Rosuvastatin for Hepatitis C</brief_title>
  <official_title>Treatment With Rosuvastatin in Patients With Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      Objective: Determine if maximum doses of rosuvastatin are safe in patients infected with&#xD;
      hepatitis C and if the so called pleiotropic effects of rosuvastatin cause a decrease in the&#xD;
      HCV viral load.&#xD;
&#xD;
      Primary study parameters: 1. to which extend causes rosuvastatin serious side effects like&#xD;
      rhabdomyolysis and hepatotoxicity in patients chronically infected with hepatitis C? 2. does&#xD;
      treatment with rosuvastatin in HCV infected patients lead to lower HCV-RNA viral load? 3. Is&#xD;
      a decrease in LDL correlated to a decrease in HCV-RNA load?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: it's a pilot study in which the patients form their own control group. A total&#xD;
      of 10 patients will be included. To evaluate the effect of maximum doses of rosuvastatin on&#xD;
      liver function and side effects, first 2 patients will be treated and evaluated. If they&#xD;
      experience no serious adverse events then a further 8 patients will be included. The dose of&#xD;
      rosuvastatin will be increased over a period of 4 weeks.&#xD;
&#xD;
      Intervention: based on experience in treating dyslipidemia, gradually increasing the dose of&#xD;
      rosuvastatin diminishes the experienced side effects and decreases the chances of developing&#xD;
      hepatotoxicity. Therefore in this study we chose to increase the dose (see flowchart).&#xD;
      Patients will start with 5 mg a day wich will be increased after 1 week to 10 mg per day.&#xD;
      After the second week of therapy a further increase to 20 mg per day is executed. This dose&#xD;
      will be given for another 2 weeks. At week 4 of treatment a further increase to 40 mg is&#xD;
      done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no actual patients recruited within year 1 after ethical committee approval&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of serious side effects like rhabdomyolysis and hepatotoxicity during treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>decrease of HCV-RNA viral load during treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>decrease of LDL during treatment</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 65 years&#xD;
&#xD;
          -  All patients with hepatitis C (all genotypes)&#xD;
&#xD;
          -  negative for hepatitis B and HIV&#xD;
&#xD;
          -  ALAT &lt; 2,5 x below the upper limit of normal&#xD;
&#xD;
          -  serological evidence of hepatitis C infection with detectable HCV-RNA (with Bayer&#xD;
             Versant HCV bDNA V3.0)&#xD;
&#xD;
          -  failed current standard of care treatment with peginterferon and ribavirin&#xD;
&#xD;
          -  WHO-score ≤1&#xD;
&#xD;
          -  fertile women must have a negative pregnancy test in the week before start of&#xD;
             medication. Use of contraceptives during the whole study-period&#xD;
&#xD;
          -  physically and mentally able to attend outpatients clinics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatitis C patiënts naive for (peg)interferon and ribavirin treatment&#xD;
&#xD;
          -  Alcohol abuses (&gt; 20 grams per day) in the last year&#xD;
&#xD;
          -  liver cirrhosis detected through liver biopsy or decompensated liver disease&#xD;
             (child-pugh B or C)&#xD;
&#xD;
          -  concomitant treatment with hepatotoxic medication / interfering with CYP450 system:&#xD;
             anti-fungal medication (voriconazole), antibiotics (gentamycine, azitromycine,&#xD;
             claritromycin, erytromycin), immuun-suppresive drugs (cyclosporine), anti-arythmia&#xD;
             (diltiazem, verapamil) and tuberculostatic drugs (rifampicin).&#xD;
&#xD;
          -  current statin use&#xD;
&#xD;
          -  active pregnancy or wish of pregnangy&#xD;
&#xD;
          -  use of grapefruit juice&#xD;
&#xD;
          -  mentally not fit to participate in the study&#xD;
&#xD;
          -  daily use of more than 2 grams of paracetamol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I.M. Hoepelman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Lokhorst, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2561-6. Epub 2005 Feb 7.</citation>
    <PMID>15699349</PMID>
  </reference>
  <reference>
    <citation>Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15865-70. Epub 2003 Dec 10.</citation>
    <PMID>14668447</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <keyword>rosuvastatin</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>geranylgeranylation</keyword>
  <keyword>HCV-RNA load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

